PortViewPortView
Gilead Sciences logo

Gilead Sciences (GILD) Stock Analysis

NASDAQHealth CareBiotechnology

$150.57+0.43%
1-year price historyRange $110.56 – $155.80
52-week range$150.57
$108.46$157.29

What Gilead Sciences does

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Key metrics

Market cap
$186.94B
P/E (TTM)
-386.08
EPS (TTM)
$-0.39
Beta
0.34
Dividend yield
2.14%
Revenue / share
$24.50
50-day avg
$135.05
200-day avg
$133.97
52-week high
$157.29
52-week low
$108.46
CEO
Daniel O'Day

ETFs linked to GILD

Broad-market and Health Care sector ETFs an investor holding Gilead Sciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how GILD fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze GILD in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Gilead Sciences?
Gilead Sciences trades under the ticker GILD on NASDAQ.
Which exchange is GILD listed on?
GILD is listed on NASDAQ.
What sector does Gilead Sciences operate in?
Gilead Sciences is classified in the Health Care sector (Biotechnology industry).
How can PortView help analyze GILD in a portfolio?
PortView shows GILD's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.